News
In brief
BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7518.652 (Published 22 September 2005) Cite this as: BMJ 2005;331:652
CJD study gets the go ahead: A study by the Medical Research Council to monitor pentosan polysulphate as a treatment for Creutzfeldt-Jakob disease (CJD) and variant CJD has received ethical approval from an NHS monitoring body. It follows two High Court cases in the UK, in which relatives sought use of this experimental treatment that has showed signs …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.